Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.